Type 2 diabetes in pediatrics and adults: Thoughts from a clinical pharmacology perspective

Journal of Pharmaceutical Sciences

Volumn 101, Issue 5, 2012, Pages 1659-1671

  Vaidyanathan, Jayabharathi ^a   Choe, Sally ^a   Sahajwalla, Chandrahas G ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Clinical Pharmacokinetics; Glimepiride; Metformin; Pediatric; Pediatric type 2 diabetes; Pharmacodynamics; Pharmacokinetics; Regulatory Science; Rosiglitazone

Indexed keywords

GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIPIZIDE; INSULIN; METFORMIN; ROSIGLITAZONE; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT DISEASE; AREA UNDER THE CURVE; CHILDHOOD DISEASE; CLINICAL PHARMACOLOGY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; GLYCEMIC CONTROL; HUMAN; INSULIN SENSITIVITY; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; REVIEW; ADOLESCENT; ADULT; CHILD; DECISION TREE; INFANT; NEWBORN; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DECISION TREES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INFANT; INFANT, NEWBORN;

EID: 84864313365     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23085     Document Type: Review

References (72)

1. Pierce M, Keen H, Bradley C. 1995. Risk of diabetes in offspring of parents with non-insulin-dependent diabetes. Diabet Med 12(1):6-13.
2. Bergman RN. 1989. Lilly lecture 1989 toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 38(12):1512-1527.
3. Weyer C, Bogardus C, Mott DM, Pratley RE. 1999. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104(6):787-794.
4. Stumvoll M, Tataranni PA, Stefan N, Vozarova B, Bogardus C. 2003. Glucose allostasis. Diabetes 52(4):903-909.
5. Dinneen S, Gerich J, Rizza R. 1992. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 327(10):707-713.
6. Boden G. 1997. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46(1):3-10.
7. American Diabetes Association. 2000. Type 2 diabetes in children and adolescents. Pediatrics 105(3):671-680.
8. Pinhas-Hamiel O, Zeitler P. 2005. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 146(5):693-700.
9. Dabelea D, Bell RA, D'Agostino RB Jr., Imperatore G, Johansen JM, Linder B, Liu LL, Loots B, Marcovina S, Mayer-Davis EJ, Pettitt DJ, Waitzfelder B. 2007. Incidence of diabetes in youth in the United States. JAMA 297(24):2716-2724.
10. Kaufman FR. 2005. Type 2 diabetes in children and youth. Endocrinol Metab Clin North Am 34(3):659-676.
11. Kaufman FR. 2003. Type 2 diabetes in children and youth. Rev Endocr Metab Disord 4(1):33-42.
12. Goran MI, Ball GD, Cruz ML. 2003. Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. J Clin Endocrinol Metab 88(4):1417-1427.
13. Food and Drug Administration: Guidance to Industry. General considerations for pediatric pharmacokinetics studies for drugs and biological products. November 10, 1998, at: http://wwwfdagov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064982htm.
14. Krakoff J, Hanson RL, Kobes S, Knowler WC. 2001. Comparison of the effect of plasma glucose concentrations on microvascular disease between Pima Indian youths and adults. Diabetes Care 24(6):1023-1028.
15. Grinstein G, Muzumdar R, Aponte L, Vuguin P, Saenger P, DiMartino-Nardi J. 2003. Presentation and 5-year follow-up of type 2 diabetes mellitus in African-American and Caribbean-Hispanic adolescents. Horm Res 60(3):121-126.
16. Turner RC, Cull CA, Frighi V, Holman RR. 1999. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 281(21):2005-2012.
17. Food and Drug Administration. Pediatric scientific activities and statistics. June 10, 2010 at: http://www.fda.gov/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch/ucm106614.htm.
18. Glucophage prescribing information. Bristol-Myers Squibb Company. August 27, 2008 at: http://wwwaccessdatafdagov/scripts/cder/drugsatfda/indexcfm.
19. Scheen AJ. 1996. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 30(5):359-371.
20. Yin OQ, Tomlinson B, Chow MS. 2006. Variability in renal clearance of substrates for renal transporters in Chinese subjects. J Clin Pharmacol 46(2):157-163.
21. Leabman MK, Giacomini KM. 2003. Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics 13(9):581-584.
22. Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee SW, Choi JH, Huang Y, Brett CM, Burchard EG, Giacomini KM. 2009. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 19(7):497-504.
23. Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG. 1995. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 35(11):1094-1102.
24. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. 2011. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50(2):81-98.
25. UK Prospective Diabetes Study (UKPDS) Group. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837-853.
26. UK Prospective Diabetes Study (UKPDS) Group. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352(9131):854-865.
27. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 2008. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359(15):1577-1589.
28. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393-403.
29. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. 2002. Effect of metformin in pediatric patients with type 2 diabetes: A randomized controlled trial. Diabetes Care 25(1):89-94.
30. Atabek ME, Pirgon O. 2008. Use of metformin in obese adolescents with hyperinsulinemia: A 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab 21(4):339-348.
31. Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F, Ward GM, Cowell CT. 2006. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: Improvement in body composition and fasting insulin. J Clin Endocrinol Metab 91(6):2074-2080.
32. Grossman SL, Lessem J. 1997. Mechanisms and clinical effects of thiazolidinediones. Expert Opin Investig Drugs 6(8):1025-1040.
33. Avandia prescribing information. GlaxoSmithKline. October 20, 2008 at: http://wwwaccessdatafdagov/scripts/cder/drugsatfda/indexcfm.
34. Clinical pharmacology review. Avandia approval package. November 20, 2001 at: http://wwwaccessdatafdagov/drugsatfda_docs/nda/99/21071_Avandiacfm.
35. Food and Drug Administration. Summaries of clinical and clinical pharmacology reviews of pediatric studies. July 7, 2011 at: http://wwwfdagov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm161894htm.
36. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ. 2007. Rosiglitazone evaluated for cardiovascular outcomes-An interim analysis. N Engl J Med 357(1):28-38.
37. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. 2001. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86(1):280-288.
38. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. 2001. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 24(2):308-315.
39. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, Freed MI. 2002. A diabetes outcome progression trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 25(10):1737-1743.
40. Jones K. American Diabetes Association's 65th Annual Scientific Session, 2005.
41. Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY). May 31, 2011 at: http://wwwclinicaltrials.gov.
42. Amaryl prescribing information. Sanofi-Aventis. June 4, 2009 at: http://wwwaccessdatafdagov/scripts/cder/drugsatfda/indexcfm.
43. Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. 1996. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 39(12):1617-1624.
44. Shukla UA, Chi EM, Lehr KH. 2004. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Ann Pharmacother 38(1):30-35.
45. Campbell RK. 1998. Glimepiride: Role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 32(10):1044-1052.
46. Goldberg RB, Holvey SM, Schneider J. 1996. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care 19(8):849-856.
47. Rosenstock J, Samols E, Muchmore DB, Schneider J. 1996. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 19(11):1194-1199.
48. Sonnenberg GE, Garg DC, Weidler DJ, Dixon RM, Jaber LA, Bowen AJ, DeChemey GS, Mullican WS, Stonesifer LD. 1997. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother 31(6):671-676.
49. Schade DS, Jovanovic L, Schneider J. 1998. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 38(7):636-641.
50. Clark CM Jr., Helmy AW. 1998. Clinical trials with glimepiride. Drugs Today (Barc) 34(5):401-408.
51. Draeger E. 1995. Clinical profile of glimepiride. Diabetes Res Clin Pract 28:S139-S146.
52. Dills DG, Schneider J. 1996. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 28(9):426-429.
53. Luis Bautista J, Bugos C, Dirnberger G, Atherton T. 2003. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: A randomized, placebo-controlled study. Clin Ther 25(1):194-209.
54. Weitgasser R, Lechleitner M, Luger A, Klingler A. 2003. Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: Results of a 1.5-year follow-up study. Diabetes Res Clin Pract 61(1):13-19.
55. Martin S, Kolb H, Beuth J, van Leendert R, Schneider B, Scherbaum WA. 2003. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: A multicentre retrospective cohort study. Diabetologia 46(12):1611-1617.
56. Gottschalk M, Danne T, Vlajnic A, Cara JF. 2007. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: A randomized, single-blind comparative study. Diabetes Care 30(4):790-794.
57. Glucovance prescribing information. Bristol-Myers Squibb Company. November 24, 2010 at: http://wwwaccessdatafdagov/scripts/cder/drugsatfda/indexcfm.
58. Zimmerman BR. 1997. Sulfonylureas. Endocrinol Metab Clin North Am 26(3):511-522.
59. Dahl-Puustinen ML, Alm C, Bertilsson L, Christenson I, Ostman J, Thunberg E, Wikstrom I. 1990. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes. Br J Clin Pharmacol 30(3):476-480.
60. Rydberg T, Jonsson A, Roder M, Melander A. 1994. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 17(9):1026-1030.
61. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M. 2004. Type 2 diabetes in the young: The evolving epidemic: The international diabetes federation consensus workshop. Diabetes Care 27(7):1798-1811.
62. Pinhas-Hamiel O, Zeitler P. 2007. Clinical presentation and treatment of type 2 diabetes in children. Pediatr Diabetes 8:16-27.
63. Sathananthan A, Vella A. 2009. Personalized pharmacotherapy for Type 2 diabetes mellitus. Per Med 6(4):417-422.
64. Hansen T, Echwald SM, Hansen L, Moller AM, Almind K, Clausen JO, Urhammer SA, Inoue H, Ferrer J, Bryan J, Aguilar-Bryan L, Permutt MA, Pedersen O. 1998. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 47(4):598-605.
65. Sesti G, Marini MA, Cardellini M, Sciacqua A, Frontoni S, Andreozzi F, Irace C, Lauro D, Gnasso A, Federici M, Perticone F, Lauro R. 2004. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 27(6):1394-1398.
66. Florez JC, Jablonski KA, Kahn SE, Franks PW, Dabelea D, Hamman RF, Knowler WC, Nathan DM, Altshuler D. 2007. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes 56(2):531-536.
67. Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JP. 2010. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: A HuGE review and meta-analysis. Am J Epidemiol 171(6):645-655.
68. Kang ES, Park SY, Kim HJ, Kim CS, Ahn CW, Cha BS, Lim SK, Nam CM, Lee HC. 2005. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 78(2):202-208.
69. Wolford JK, Yeatts KA, Dhanjal SK, Black MH, Xiang AH, Buchanan TA, Watanabe RM. 2005. Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes 54(11):3319-3325.
70. de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, Danhof M. 2006. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J Pharmacokinet Pharmacodyn 33(3):313-343.
71. Gobburu JV, Lesko LJ. 2009. Quantitative disease, drug, and trial models. Annu Rev Pharmacol Toxicol 49:291-301.
72. Jadhav PR, Zhang J, Gobburu JV. 2009. Leveraging prior quantitative knowledge in guiding pediatric drug development: A case study. Pharm Stat 8(3):216-224.